Cargando…

Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy

Immune-checkpoint signaling plays an important role in immunosuppression of tumors. We aimed to investigate the association of soluble programmed death-ligand 1 (sPD-L1) level in plasma with overall survival (OS) in locally advanced or inoperable nonsmall-cell lung cancer (NSCLC) patients treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jing, Zhang, Peng, Wang, Jianhua, Xi, Qingsong, Zhao, Xueqi, Ji, Minghua, Hu, Guangyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319514/ https://www.ncbi.nlm.nih.gov/pubmed/28207525 http://dx.doi.org/10.1097/MD.0000000000006102

Ejemplares similares

Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy
por: Koh, Young W., et al.
Publicado: (2017)

Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer – A retrospective analysis
por: Kong, Pengyu, et al.
Publicado: (2017)

Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy?
por: Nguyen, Nam P., et al.
Publicado: (2016)

The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis
por: Luo, Hui, et al.
Publicado: (2017)

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
por: Cui, Guanghui, et al.
Publicado: (2017)

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis
por: Wei, Wei, et al.
Publicado: (2018)

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports
por: Koba, Taro, et al.
Publicado: (2017)

Clinical and prognostic significance of Merkel cell polyomavirus in nonsmall cell lung cancer
por: Kim, Gun-Jik, et al.
Publicado: (2017)

A comprehensive bioinformatics analysis of FOXP3 in nonsmall cell lung cancer
por: Zhu, Jianfei, et al.
Publicado: (2022)

CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study
por: Zhao, Tongwei, et al.
Publicado: (2016)

Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer
por: Zhang, Xiaojun, et al.
Publicado: (2017)

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
por: Ding, Lin, et al.
Publicado: (2016)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

Are heart doses associated with survival in patients with non-small cell lung cancer who received post-operative thoracic radiotherapy?: A national population-based study
por: Lee, Chia Ching, et al.
Publicado: (2019)

The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
por: Zhang, Yaxiong, et al.
Publicado: (2015)

CXCL14 and NOS1 expression in specimens from patients with stage I–IIIA nonsmall cell lung cancer after curative resection
por: Ji, Xiaoqin, et al.
Publicado: (2018)

Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study
por: Liu, Qingyun, et al.
Publicado: (2021)

Effect of mu Agonists on Long-Term Survival and Recurrence in Nonsmall Cell Lung Cancer Patients
por: Wang, Kai, et al.
Publicado: (2015)

Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study
por: Yang, Jia, et al.
Publicado: (2019)

(125)I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy
por: Xiang, Zhanwang, et al.
Publicado: (2015)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression
por: An, Na, et al.
Publicado: (2016)

Tonsillar metastasis of nonsmall cell lung cancer with G719S mutation in exon 18: A case report
por: Wu, Yimin, et al.
Publicado: (2017)

Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer
por: Liang, Wenjun, et al.
Publicado: (2016)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

Predictors for improvement of xerostomia in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy
por: Pan, Xin-Bin, et al.
Publicado: (2019)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
por: Chang, Chia-Hao, et al.
Publicado: (2015)

Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Preliminary study on the clinical significance of kinesin Kif18a in nonsmall cell lung cancer: An analysis of 100 cases
por: Guo, Weifeng, et al.
Publicado: (2020)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports
por: Lu, Chieh-Sheng, et al.
Publicado: (2017)

Contribution of age at diagnosis to cancer-specific survival of nasopharyngeal carcinoma patients receiving radiotherapy
por: Zhang, Wei-Ming, et al.
Publicado: (2023)

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis
por: Gu, Biao, et al.
Publicado: (2016)

Lymph node dissection and survival in patients with early stage nonsmall cell lung cancer: A 10-year cohort study
por: Shen-Tu, Yang, et al.
Publicado: (2017)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
por: Ding, Wei, et al.
Publicado: (2020)

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis
por: Liu, Yafang, et al.
Publicado: (2016)

Prognostic Model of Death and Distant Metastasis for Nasopharyngeal Carcinoma Patients Receiving 3DCRT/IMRT in Nonendemic Area of China
por: Zang, Jian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hibi3cj0bnt5nd29gtlcvoiueh